Sciensus’ Post

Launching an orphan drug in Europe has never been more challenging. The stakes are high. Stricter regulation. Tougher pricing negotiations. Growing influence from patient advocacy groups. The European market is more complex than ever and without the right strategy, delays, restricted access or commercial failure are real risks. Join our expert webinar to learn how to navigate market access, pricing and patient engagement in 2025. What you'll learn: - Why early patient engagement is critical for regulatory success and long-term adoption - The latest trends in European pricing and reimbursement and how to stay ahead - How collaborating with patient advocacy groups can unlock new market access opportunities If you're involved in orphan drug development, this is your chance to get practical, expert-backed strategies to accelerate access and maximise commercial success. Join Raymond A. Huml, Vice President of Rare Strategy at Sciensus, and Andrew Cummins, Vice President of Business Development at Sciensus, along with Kirsty Hoyle, CEO of Metabolic Support UK, on 28th March at 10am PDT / 1pm EDT / 5pm GMT. Register now: https://lnkd.in/eUyzcer8 #OrphanDrugs #MarketAccess #RegulatoryAffairs #PharmaStrategy #Biotech #RareDisease #LifeSciences Xtalks